CRIMI study

Dr. M.J. Remmelink (NL) presented at EMUC23 the CRIMI study: The 3 year follow-up of the phase 1b-2 study on chemoradiotherapy combined with nivolumab monotherapy or ipilimumab and nivolumab in muscle-invasive bladder cancer.